Noréns advises private equity giant EQT on patent matters in connection with the acquisition of the biotech company Mabtech.
Mabtech is a leading provider of antibodies, kits and platforms for life science research. The company is based in Sweden and has over 900 customers in more than 60 countries. The company had a turnover of 247 million SEK and made a profit of 76 million SEK in 2022.
As of 2022, EQT’s assets under management are €210 billion / US$227 billion and it is ranked the third largest private equity firm worldwide based on funds raised. The transaction is subject to conditions and approvals and is expected to close in Q1 2024.
The Noréns team consisted of Anders Bratt and Johan Ståhlberg.
